Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: Influence on clinical symptoms and nasal allergic inflammation

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 3, 2004, Pages 280-288

  Kurowski, M ^a   Kuna, P ^a   Gorski P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Allergic inflammation; Allergic rhinitis; Antihistamines; Antileukotrienes; Prophylaxis

Indexed keywords

CETIRIZINE; EOSINOPHIL CATIONIC PROTEIN; MONTELUKAST; PLACEBO; TRYPTASE;

ADULT; ALLERGIC RHINITIS; ARTICLE; BASOPHIL; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; EVALUATION; FEMALE; GRASS POLLEN; HUMAN; INFLAMMATION; MALE; MEDICAL RECORD; NASAL PRURITUS; NOSE ALLERGY; NOSE MUCUS; OCULAR PRURITUS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SAMPLING; SCORING SYSTEM; SEASON; SNEEZING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ACETATES; ADOLESCENT; ADULT; CETIRIZINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; SERINE ENDOPEPTIDASES; TRYPTASES;

EID: 1542510017     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1398-9995.2003.00416.x     Document Type: Article

References (35)

1. BENTLEY AM, JACOBSON MR, CUMBERWORTH V, BARKANS JR, MOQBEL R, SCHWARTZ LB, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89:877-883.
2. JUILIUSSON S, PIPKORN U, KARLSSON G, ENERBACK L. Mast cells and eosinophils in the allergic mucosal response to allergen challenge: changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol 1992;90:898-909.
3. HAKANSSON L, RAK S, DAHL R, VENGE P. The formation of eosinophil and neutrophil chemotactic activity during a pollen season and after allergen challenge. J Allergy Clin Immunol 1989;83:933-939.
4. FOKKENS WJ, BROEKHUIS-FLUITSMA DM, RIJNTJES E, VROOM TM, HOEFSMIT EC. Langerhans cells in nasal mucosa of patients with grass pollen allergy. Immunobiology 1991;182:135-142.
5. NACLERIO RM, MEIER HL, KAGEY-SOEOTKA A, ADKINSON NF, MEYERS DA, NORMAN PS, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128: 597-602.
6. WANG D, CLEMENT P, SMITZ J, DE WAELE M, DERDE M-P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995;106: 278-285.
7. KNANI J, CAMPBELL A, ENANDER I, PETERSON CGB, MICHEL F-B, BOUSQUET J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992;90:880-889.
8. WILSON SJ, LAU L, HOWARTH PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy 1998;28:220-227.
9. WANG D, CLEMENT P, SMITZ J, DE WAELE M, DERDE M-P. Monitoring nasal allergic inflammation by measuring the concentration of eosinophil cationic protein and eosinophils in nasal secretions. Allergy 1995;50:147-151.
10. SIM TC, GRANT JA, HILSMEIER KA, FUKUDA Y, ALAM R. Proinflammatoty cytokines in nasal secretions of allergic subjects after allergen challenge. Am J Respir Crit Care Med 1994;149:339-344.
11. MYGIND N, SECHER C, KIRKEGAARD J. Role of histamine and antihistamines in the nose. Eur J Respir Dis 1983;64: 16-20.
12. HOWARTH PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997;52:12-18.
13. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-297.
14. BOUSQUET J, VAN CAUWENBERGE P, BACHERT C, CANONICA GW, DEMOLY P, DURHAM SR, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003;58:192-197.
15. MELTZER EO, MALMSTROM K, LU S, PRENNER BM, WEI LX, WEINSTEIN SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-922.
16. PULLERITS T, PRAKS L, RISTIOJA V, LÖTVALL J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-955.
17. NAYAK AS, PHILIP G, LU S, MALICE MP, REISS TF, Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600.
18. PHILIP G, MALMSTROM K, HAMPEL FC Jr, WEINSTEIN SF, LAFORCE CF, RATNER PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2003;32:1020-1028.
19. CIPRANDI G, BUSCAGLIA S, IUDICE A, CANONICA GW. Protective effects of different doses of terfenadine on the conjunctival provocation test. Allergy 1992;47:309-312.
20. STERN MA, DARNELL R, TUDOR D. Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season? Allergy 1997;52:440-444.
21. JUNIPER EF, KLINE PA, HARGREAVE FE, DOLOVICH J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989;83: 627-633.
22. JACOBI HH, SKOV PS, POULSEN LK, MALLING H-J, MYGIND N. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999;103:768-772.
23. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N and the Workshop Expert Panel. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 2002;57:841-855.
24. DEMOLY P, ALLAERT F-A, LECASBLE M, BOUSQUET J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58: 672-675.
25. GREIFF L, PIPKORN U, ALKNER U, PERSSON CGA. The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exsudations/secretions. Clin Exp Allergy 1990;20:253-259.
26. NATHAN RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003;90:182-190.
27. WINTHER L, MOSEHOLM L, REIMERT CM, STAHL SKOV P, KÆRGAARD POULSEN L. Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy 1999;54:436-445.
28. PULLERITS T, PRAKS L, SKOOGH B-E, ANI R, LÖTVALL J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999;159:1814-1818.
29. WU AY, CHIK SC, CHAN AW, LI Z, TSANG KW, LI W. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy 2003;33:359-366.
30. KLEINJAN A, MCEUEN AR, DIJKSTRA MD, BUCKLEY MG, WALLS AF, FOKKENS WJ. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000;106:677-686.
31. BRAUNSTAHL G-J, OVERBEEK SE, FOKKENS WJ, KLEINJAN A, MCEUEN AR, WALLS AF, et al. Segmental broncho-provocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001;164:858-865.
32. WILSON DR, IRANI A-MA, WALKER SM, JACOBSON MR, MACKAY IS, SCHWARTZ LB, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001;31:1705-1713.
33. CALHOUN WJ, LAVINS BJ, MINKWITZ MC, EVANS R, GLEICH GJ, COHN J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Crit Care Med 1998;157: 1381-1389.
34. STELMACH I, JERZYNSKA J, KUNA P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002;109:257-263.
35. CASTELLS M, SCHWARTZ LB. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol 1988;82:348-355.